D018074Chemicals & DrugsD20.215.894.865.900D23.050.865.9007140.986241Vaccines, Conjugateprns:emailEncryptedemail addressFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMicrobiology and ImmunologyWake Forest School of MedicineKatherinePoehlingKatherine A. Poehling MD, MPH36.08915800000000-80.26686200000000545Poehling, KatherineProfessorMarthaAlexander-Miller4MC38pybvDqOTrPFxxARchSSnXEUZ/41PeKUY3jDi/Sa+yrfEF0=Martha A. Alexander-Miller PhD36.09032400000000-80.26649100000000603Alexander-Miller, MarthaProfessorMarlenaWestcottMarlena M. Westcott PhD36.09032400000000-80.26649100000000697Westcott, MarlenaAssociate Professor26425548Tusé D, Ku N, Bendandi M, Becerra C, Collins R, Langford N, Sancho SI, López-Díaz de Cerio A, Pastor F, Kandzia R, Thieme F, Jarczowski F, Krause D, Ma JK, Pandya S, Klimyuk V, Gleba Y, Butler-Ransohoff JEBioMed research internationalTusé D, Ku N, Bendandi M, Becerra C, Collins R, Langford N, Sancho SI, López-Díaz de Cerio A, Pastor F, Kandzia R, Thieme F, Jarczowski F, Krause D, Ma JK, Pandya S, Klimyuk V, Gleba Y, Butler-Ransohoff JE. Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma. Biomed Res Int. 2015; 2015:648143.Biomed Res Int2015-09-06T00:00:002015Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.28510699Olarte L, Barson WJ, Bradley JS, Tan TQ, Lin PL, Romero JR, Givner LB, Hoffman JA, Hultén KG, Mason EO, Kaplan SLJournal of the Pediatric Infectious Diseases SocietyOlarte L, Barson WJ, Bradley JS, Tan TQ, Lin PL, Romero JR, Givner LB, Hoffman JA, Hultén KG, Mason EO, Kaplan SL. Invasive Pneumococcal Disease in Infants Aged 0-60 Days in the United States in the 13-Valent Pneumococcal Conjugate Vaccine Era. J Pediatric Infect Dis Soc. 2018 Aug 17; 7(3):249-252.J Pediatric Infect Dis Soc2018-08-17T00:00:002018Invasive Pneumococcal Disease in Infants Aged 0-60 Days in the United States in the 13-Valent Pneumococcal Conjugate Vaccine Era.29398273Westcott MM, Clemens EA, Holbrook BC, King SB, Alexander-Miller MAVaccineWestcott MM, Clemens EA, Holbrook BC, King SB, Alexander-Miller MA. The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells. Vaccine. 2018 02 21; 36(9):1174-1182.Vaccine2018-02-21T00:00:002018The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells.ThomasWierzbaThomas F. Wierzba PhD, MS, MPH2349Wierzba, ThomasProfessor20Professor22276104Kim SH, Pezzoli L, Yacouba H, Coulibaly T, Djingarey MH, Perea WA, Wierzba TFPloS oneKim SH, Pezzoli L, Yacouba H, Coulibaly T, Djingarey MH, Perea WA, Wierzba TF. Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010. PLoS One. 2012; 7(1):e29116.PLoS One2012-01-20T00:00:002012Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010.Implementation Science (Public Health Sciences)Internal Medicine, Infectious DiseasesPediatrics, GeneralCaraJanuszCara B. Janusz3533Janusz, CaraAssistant Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessor17015528Szilagyi PG, Griffin MR, Shone LP, Barth R, Zhu Y, Schaffer S, Ambrose S, Roy J, Poehling KA, Edwards KM, Walker FJ, Schwartz BPediatricsSzilagyi PG, Griffin MR, Shone LP, Barth R, Zhu Y, Schaffer S, Ambrose S, Roy J, Poehling KA, Edwards KM, Walker FJ, Schwartz B. The impact of conjugate pneumococcal vaccination on routine childhood vaccination and primary care use in 2 counties. Pediatrics. 2006 Oct; 118(4):1394-402.Pediatrics2006-10-01T00:00:002006The impact of conjugate pneumococcal vaccination on routine childhood vaccination and primary care use in 2 counties.0.6783390.1726087research area of0.6813210.054735617subject area for